CD164 promotes lung tumor-initiating cells with stem cell activity and determines tumor growth and drug resistance via Akt/mTOR signaling.
Identifieur interne : 000903 ( Main/Exploration ); précédent : 000902; suivant : 000904CD164 promotes lung tumor-initiating cells with stem cell activity and determines tumor growth and drug resistance via Akt/mTOR signaling.
Auteurs : Wei-Liang Chen [République populaire de Chine] ; Ai-Fang Huang [République populaire de Chine] ; Shih-Ming Huang [République populaire de Chine] ; Ching-Liang Ho [République populaire de Chine] ; Yung-Lung Chang [République populaire de Chine] ; James Yi-Hsin Chan [République populaire de Chine]Source :
- Oncotarget [ 1949-2553 ] ; 2017.
Abstract
CD164 is a cell adhesion molecule that increases hematopoietic stem cell proliferation, adhesion, and migration via C-X-C chemokine receptor type 4 (CXCR4) signaling. Emerging evidence indicates that elevated CD164 expression is associated with aggressive metastasis, advanced stages, and shorter overall survival in lung cancer. However, no data are available regarding the clinical significance of CD164 expression in lung cancer. This study explores whether CD164 promotes tumor-initiation and drug resistance through the stem cell property. Using tissue microarrays, we determine that CD164 expression is correlated with clinicopathological characteristics in human lung cancer. The CD164 overexpression in normal lung epithelial cells (BEAS2B cells) leads to malignant transformation in vitro, tumorigenicity in xenografted mice, stem cell-like property, and drug resistance through ATP-binding cassette transporters. The CD164 overexpression increases CXCR4 expression and activates Akt/mTOR signaling. Rapamycin, an mTOR inhibitor, hinders cell proliferation along with sphere formation in vitro and impedes tumor growth in vivo. In conclusion, we have provided evidence that CD164 promotes the growth of lung tumor-initiating cells with stem cell properties and induces tumor growth and drug resistance through Akt/mTOR signaling. Therefore, identification of CD164 as a cancer stem cell therapeutic marker may develop an effective therapy in patients with chemoresistant lung cancer.
DOI: 10.18632/oncotarget.11132
PubMed: 28903328
PubMed Central: PMC5589567
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">CD164 promotes lung tumor-initiating cells with stem cell activity and determines tumor growth and drug resistance via Akt/mTOR signaling.</title><author><name sortKey="Chen, Wei Liang" sort="Chen, Wei Liang" uniqKey="Chen W" first="Wei-Liang" last="Chen">Wei-Liang Chen</name><affiliation wicri:level="1"><nlm:affiliation>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Division of Family Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, and School of Medicine, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of Family Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, and School of Medicine, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Division of Geriatric Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, and School of Medicine, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of Geriatric Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, and School of Medicine, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Ai Fang" sort="Huang, Ai Fang" uniqKey="Huang A" first="Ai-Fang" last="Huang">Ai-Fang Huang</name><affiliation wicri:level="1"><nlm:affiliation>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Shih Ming" sort="Huang, Shih Ming" uniqKey="Huang S" first="Shih-Ming" last="Huang">Shih-Ming Huang</name><affiliation wicri:level="1"><nlm:affiliation>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Ho, Ching Liang" sort="Ho, Ching Liang" uniqKey="Ho C" first="Ching-Liang" last="Ho">Ching-Liang Ho</name><affiliation wicri:level="1"><nlm:affiliation>Division of Hematology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of Hematology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Chang, Yung Lung" sort="Chang, Yung Lung" uniqKey="Chang Y" first="Yung-Lung" last="Chang">Yung-Lung Chang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Chan, James Yi Hsin" sort="Chan, James Yi Hsin" uniqKey="Chan J" first="James Yi-Hsin" last="Chan">James Yi-Hsin Chan</name><affiliation wicri:level="1"><nlm:affiliation>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Microbiology and Immunology, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28903328</idno><idno type="pmid">28903328</idno><idno type="doi">10.18632/oncotarget.11132</idno><idno type="pmc">PMC5589567</idno><idno type="wicri:Area/Main/Corpus">000730</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000730</idno><idno type="wicri:Area/Main/Curation">000730</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000730</idno><idno type="wicri:Area/Main/Exploration">000730</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">CD164 promotes lung tumor-initiating cells with stem cell activity and determines tumor growth and drug resistance via Akt/mTOR signaling.</title><author><name sortKey="Chen, Wei Liang" sort="Chen, Wei Liang" uniqKey="Chen W" first="Wei-Liang" last="Chen">Wei-Liang Chen</name><affiliation wicri:level="1"><nlm:affiliation>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Division of Family Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, and School of Medicine, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of Family Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, and School of Medicine, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Division of Geriatric Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, and School of Medicine, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of Geriatric Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, and School of Medicine, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Ai Fang" sort="Huang, Ai Fang" uniqKey="Huang A" first="Ai-Fang" last="Huang">Ai-Fang Huang</name><affiliation wicri:level="1"><nlm:affiliation>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Shih Ming" sort="Huang, Shih Ming" uniqKey="Huang S" first="Shih-Ming" last="Huang">Shih-Ming Huang</name><affiliation wicri:level="1"><nlm:affiliation>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Ho, Ching Liang" sort="Ho, Ching Liang" uniqKey="Ho C" first="Ching-Liang" last="Ho">Ching-Liang Ho</name><affiliation wicri:level="1"><nlm:affiliation>Division of Hematology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of Hematology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Chang, Yung Lung" sort="Chang, Yung Lung" uniqKey="Chang Y" first="Yung-Lung" last="Chang">Yung-Lung Chang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Chan, James Yi Hsin" sort="Chan, James Yi Hsin" uniqKey="Chan J" first="James Yi-Hsin" last="Chan">James Yi-Hsin Chan</name><affiliation wicri:level="1"><nlm:affiliation>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Microbiology and Immunology, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author></analytic><series><title level="j">Oncotarget</title><idno type="eISSN">1949-2553</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">CD164 is a cell adhesion molecule that increases hematopoietic stem cell proliferation, adhesion, and migration via C-X-C chemokine receptor type 4 (CXCR4) signaling. Emerging evidence indicates that elevated CD164 expression is associated with aggressive metastasis, advanced stages, and shorter overall survival in lung cancer. However, no data are available regarding the clinical significance of CD164 expression in lung cancer. This study explores whether CD164 promotes tumor-initiation and drug resistance through the stem cell property. Using tissue microarrays, we determine that CD164 expression is correlated with clinicopathological characteristics in human lung cancer. The CD164 overexpression in normal lung epithelial cells (BEAS2B cells) leads to malignant transformation <i>in vitro</i>, tumorigenicity in xenografted mice, stem cell-like property, and drug resistance through ATP-binding cassette transporters. The CD164 overexpression increases CXCR4 expression and activates Akt/mTOR signaling. Rapamycin, an mTOR inhibitor, hinders cell proliferation along with sphere formation <i>in vitro</i> and impedes tumor growth <i>in vivo</i>. In conclusion, we have provided evidence that CD164 promotes the growth of lung tumor-initiating cells with stem cell properties and induces tumor growth and drug resistance through Akt/mTOR signaling. Therefore, identification of CD164 as a cancer stem cell therapeutic marker may develop an effective therapy in patients with chemoresistant lung cancer.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28903328</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1949-2553</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>33</Issue><PubDate><Year>2017</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Oncotarget</Title><ISOAbbreviation>Oncotarget</ISOAbbreviation></Journal><ArticleTitle>CD164 promotes lung tumor-initiating cells with stem cell activity and determines tumor growth and drug resistance via Akt/mTOR signaling.</ArticleTitle><Pagination><MedlinePgn>54115-54135</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.11132</ELocationID><Abstract><AbstractText>CD164 is a cell adhesion molecule that increases hematopoietic stem cell proliferation, adhesion, and migration via C-X-C chemokine receptor type 4 (CXCR4) signaling. Emerging evidence indicates that elevated CD164 expression is associated with aggressive metastasis, advanced stages, and shorter overall survival in lung cancer. However, no data are available regarding the clinical significance of CD164 expression in lung cancer. This study explores whether CD164 promotes tumor-initiation and drug resistance through the stem cell property. Using tissue microarrays, we determine that CD164 expression is correlated with clinicopathological characteristics in human lung cancer. The CD164 overexpression in normal lung epithelial cells (BEAS2B cells) leads to malignant transformation <i>in vitro</i>, tumorigenicity in xenografted mice, stem cell-like property, and drug resistance through ATP-binding cassette transporters. The CD164 overexpression increases CXCR4 expression and activates Akt/mTOR signaling. Rapamycin, an mTOR inhibitor, hinders cell proliferation along with sphere formation <i>in vitro</i> and impedes tumor growth <i>in vivo</i>. In conclusion, we have provided evidence that CD164 promotes the growth of lung tumor-initiating cells with stem cell properties and induces tumor growth and drug resistance through Akt/mTOR signaling. Therefore, identification of CD164 as a cancer stem cell therapeutic marker may develop an effective therapy in patients with chemoresistant lung cancer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei-Liang</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Family Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, and School of Medicine, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Geriatric Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, and School of Medicine, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ai-Fang</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shih-Ming</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Ching-Liang</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Division of Hematology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yung-Lung</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>James Yi-Hsin</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Oncotarget</MedlineTA><NlmUniqueID>101532965</NlmUniqueID><ISSNLinking>1949-2553</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD164</Keyword><Keyword MajorTopicYN="N">cancer stem cell</Keyword><Keyword MajorTopicYN="N">drug resistance</Keyword><Keyword MajorTopicYN="N">lung cancer</Keyword><Keyword MajorTopicYN="N">tumorigenesis</Keyword></KeywordList><CoiStatement>CONFLICTS OF INTEREST The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>05</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>07</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28903328</ArticleId><ArticleId IdType="doi">10.18632/oncotarget.11132</ArticleId><ArticleId IdType="pii">11132</ArticleId><ArticleId IdType="pmc">PMC5589567</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Med. 2011 Aug 07;17(9):1101-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21822286</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biochem. 2011 Sep;355(1-2):241-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21553023</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010 Nov 19;5(11):e14062</Citation><ArticleIdList><ArticleId IdType="pubmed">21124918</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1998 Aug 1;92(3):849-66</Citation><ArticleIdList><ArticleId IdType="pubmed">9680353</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2013 Nov 15;3:3230</Citation><ArticleIdList><ArticleId IdType="pubmed">24231729</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Pharmacol. 2014 Aug 1;90(3):197-207</Citation><ArticleIdList><ArticleId IdType="pubmed">24863259</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2007 Mar 1;109 (5):1825-33</Citation><ArticleIdList><ArticleId IdType="pubmed">17077324</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Pathol. 1995 Sep;48(9):876-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7490328</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2016 Feb;158:71-90</Citation><ArticleIdList><ArticleId IdType="pubmed">26706243</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2007 May 15;67(10):4827-33</Citation><ArticleIdList><ArticleId IdType="pubmed">17510412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cancer Res. 2009 Mar;7(3):330-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19276181</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Cancer. 2009 Apr;9(4):265-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19262571</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Biochem Biophys. 2014 Jul;69(3):389-98</Citation><ArticleIdList><ArticleId IdType="pubmed">24549856</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2009 Nov 25;139(5):871-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19945376</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 2016 Mar 28;372(2):147-56</Citation><ArticleIdList><ArticleId IdType="pubmed">26797015</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2008 Mar;15(3):504-14</Citation><ArticleIdList><ArticleId IdType="pubmed">18049477</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Drug Metab Toxicol. 2009 Dec;5(12 ):1529-42</Citation><ArticleIdList><ArticleId IdType="pubmed">19708828</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15449-54</Citation><ArticleIdList><ArticleId IdType="pubmed">20713713</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1998 Oct 15;92(8):2613-28</Citation><ArticleIdList><ArticleId IdType="pubmed">9763543</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Cancer. 2006 Jul 21;6:195</Citation><ArticleIdList><ArticleId IdType="pubmed">16859559</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Pharmacol Sin. 2013 Jun;34(6):732-40</Citation><ArticleIdList><ArticleId IdType="pubmed">23685952</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Cell Biol. 2010 Apr;22(2):169-76</Citation><ArticleIdList><ArticleId IdType="pubmed">19945836</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2013 Nov 8;342(6159):1234850</Citation><ArticleIdList><ArticleId IdType="pubmed">24202173</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 2013 Aug 9;336(1):96-105</Citation><ArticleIdList><ArticleId IdType="pubmed">23603434</ArticleId></ArticleIdList></Reference><Reference><Citation>Breast. 2011 Feb;20(1):78-85</Citation><ArticleIdList><ArticleId IdType="pubmed">20810282</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Med. 2014 Jul;34(1):237-43</Citation><ArticleIdList><ArticleId IdType="pubmed">24756834</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Ther Targets. 2016;20(4):393-405</Citation><ArticleIdList><ArticleId IdType="pubmed">26878385</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2011 Apr 1;71(7):2541-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21447735</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Cell Mol Biol. 1997 Sep;17(3):353-60</Citation><ArticleIdList><ArticleId IdType="pubmed">9308922</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancers (Basel). 2010 Aug 18;2(3):1576-96</Citation><ArticleIdList><ArticleId IdType="pubmed">24281174</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2004 Jan 22;350(4):379-92</Citation><ArticleIdList><ArticleId IdType="pubmed">14736930</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2006 Mar 30;25(14):2105-12</Citation><ArticleIdList><ArticleId IdType="pubmed">16288213</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2010 Apr 24;86(17-18):631-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20159023</ArticleId></ArticleIdList></Reference><Reference><Citation>CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29</Citation><ArticleIdList><ArticleId IdType="pubmed">22237781</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2012 Apr 20;420(4):869-74</Citation><ArticleIdList><ArticleId IdType="pubmed">22449574</ArticleId></ArticleIdList></Reference><Reference><Citation>Breast Cancer Res. 2012 Oct 31;14(5):R139</Citation><ArticleIdList><ArticleId IdType="pubmed">23113900</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Des Devel Ther. 2015 Jun 24;9:3267-78</Citation><ArticleIdList><ArticleId IdType="pubmed">26150700</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2015 May 28;5:10357</Citation><ArticleIdList><ArticleId IdType="pubmed">26020117</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Anticancer Ther. 2011 Apr;11(4):621-30</Citation><ArticleIdList><ArticleId IdType="pubmed">21504328</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2009 Jun 10;27(17):2793-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19414676</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharm. 2012 Nov 5;9(11):3147-59</Citation><ArticleIdList><ArticleId IdType="pubmed">23046348</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Cell. 2011 Jun 14;19(6):754-64</Citation><ArticleIdList><ArticleId IdType="pubmed">21665149</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2012 Apr 1;18(7):1863-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22344233</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Transl Oncol. 2011 May;13(5):289-93</Citation><ArticleIdList><ArticleId IdType="pubmed">21596655</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Invest. 2012 Jun;30(5):380-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22409183</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chest Med. 2011 Dec;32(4):703-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22054881</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2012 Jan 20;148(1-2):259-72</Citation><ArticleIdList><ArticleId IdType="pubmed">22225612</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Cell. 2012 Dec 11;22(6):709-24</Citation><ArticleIdList><ArticleId IdType="pubmed">23201163</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cancer. 2013 Oct 05;12(1):115</Citation><ArticleIdList><ArticleId IdType="pubmed">24094005</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6124-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22454501</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2012 Jan 1;72(1):100-11</Citation><ArticleIdList><ArticleId IdType="pubmed">22080568</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanomedicine (Lond). 2012 Apr;7(4):597-615</Citation><ArticleIdList><ArticleId IdType="pubmed">22471722</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2000 Jul 15;165(2):840-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10878358</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 1999 Jul 29;18(30):4336-47</Citation><ArticleIdList><ArticleId IdType="pubmed">10439041</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Pathol. 2008 Jul;39(7):1096-102</Citation><ArticleIdList><ArticleId IdType="pubmed">18495204</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2005 Feb 15;65(4):1541-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15735043</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Chen, Wei Liang" sort="Chen, Wei Liang" uniqKey="Chen W" first="Wei-Liang" last="Chen">Wei-Liang Chen</name></noRegion><name sortKey="Chan, James Yi Hsin" sort="Chan, James Yi Hsin" uniqKey="Chan J" first="James Yi-Hsin" last="Chan">James Yi-Hsin Chan</name><name sortKey="Chan, James Yi Hsin" sort="Chan, James Yi Hsin" uniqKey="Chan J" first="James Yi-Hsin" last="Chan">James Yi-Hsin Chan</name><name sortKey="Chan, James Yi Hsin" sort="Chan, James Yi Hsin" uniqKey="Chan J" first="James Yi-Hsin" last="Chan">James Yi-Hsin Chan</name><name sortKey="Chang, Yung Lung" sort="Chang, Yung Lung" uniqKey="Chang Y" first="Yung-Lung" last="Chang">Yung-Lung Chang</name><name sortKey="Chen, Wei Liang" sort="Chen, Wei Liang" uniqKey="Chen W" first="Wei-Liang" last="Chen">Wei-Liang Chen</name><name sortKey="Chen, Wei Liang" sort="Chen, Wei Liang" uniqKey="Chen W" first="Wei-Liang" last="Chen">Wei-Liang Chen</name><name sortKey="Ho, Ching Liang" sort="Ho, Ching Liang" uniqKey="Ho C" first="Ching-Liang" last="Ho">Ching-Liang Ho</name><name sortKey="Huang, Ai Fang" sort="Huang, Ai Fang" uniqKey="Huang A" first="Ai-Fang" last="Huang">Ai-Fang Huang</name><name sortKey="Huang, Shih Ming" sort="Huang, Shih Ming" uniqKey="Huang S" first="Shih-Ming" last="Huang">Shih-Ming Huang</name><name sortKey="Huang, Shih Ming" sort="Huang, Shih Ming" uniqKey="Huang S" first="Shih-Ming" last="Huang">Shih-Ming Huang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000903 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000903 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28903328
|texte= CD164 promotes lung tumor-initiating cells with stem cell activity and determines tumor growth and drug resistance via Akt/mTOR signaling.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28903328" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |